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ABSTRACT
Natural killer (NK) cell neoplasms are characterized by clonal proliferation of 
cytotoxic NK cells. Since there is no standard treatment to date, new therapeutic 
options are needed, especially for NK aggressive tumors. Fyn tyrosine kinase has a key 
role in different biological processes, such as cell growth and differentiation, being 
also involved in the pathogenesis of hematologic malignancies. Our previous studies 
led us to identify 4c pyrazolo[3,4-d]pyrimidine compound capable of inhibiting Fyn 
activation and inducing apoptosis in different cancer cell lines. Here we investigated 
the presence of Fyn and the effect of its inhibitor in NK malignant cells. Firstly, 
we showed Fyn over-expression in NK leukemic cells compared to peripheral blood 
mononuclear cells from healthy donors. Subsequently, we demonstrated that 4c 
treatment reduced cell viability, induced caspase 3-mediate apoptosis and cell cycle 
arrest in NK cells. Moreover, by inhibiting Fyn phosphorylation, 4c compound reduced 
Akt and P70 S6 kinase activation and changed the expression of genes involved in 
cell death and survival in NK cells. Our study demonstrated that Fyn is involved in 
the pathogenesis of NK leukemia and that it could represent a potential target for 
this neoplasm. Moreover, we proved that Fyn inhibitor pyrazolo[3,4-d]pyrimidine 
compound, could be a started point to develop new therapeutic agents.
INTRODUCTION
Natural Killer (NK) cell neoplasms are a rare 
and heterogeneous group of disorders characterized by 
excessive proliferation of cytotoxic CD3− CD16/56+ NK 
cells. This group comprises two subtypes: aggressive 
NK leukemia (ANKL) and chronic lymphoproliferative 
disorder (CLPD) [1, 2]. ANKL is an Epstein Barr virus 
(EBV)-associated tumor most prevalent among Asian 
young adults (median age of 42 years). It has a fulminant 
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clinical course, frequently resulting in death within 
two months. In contrast, CLPD has no demonstrable 
association with EBV and tends to occur in older adults 
(median age of 60 years). The clinical course is typically 
indolent, similarly to T-cell large granular lymphocytes 
leukemia (T-LGLL) [3–5].
Since no standard therapies for aggressive NK cell 
neoplasms have been established so far and the overall 
outcomes are dismal, new therapeutic options are needed.
Fyn, a tyrosine-specific phospho-transferase, is a 
member of Src family kinases which includes c-Src, Yes, 
Lck, Lyn, Hck, Fgr and Blk [6–8]. It phosphorylates a 
variety of target proteins involved in different signaling 
pathways [6]. Moreover, it regulates several biological 
functions, including growth factor and cytokine receptor 
signaling, cell-cell adhesion, integrin-mediated signaling, 
ion channel function, platelet activation, T and B-cell 
receptor signaling, axon guidance, mitosis, differentiation 
of NK cells [9–11].
In the last decade, the implication of Fyn in cancer 
biology and in hematologic malignancies has become 
more apparent. In chronic myeloid leukemia (CML) Fyn 
is up-regulated and its activation seems to be important in 
imatinib resistance [12, 13]. It is notably involved in the 
pathogenesis of peripheral T cell lymphomas [14] and in 
acute myeloid leukemia its higher expression, combined 
to FLT3-Internal Tandem Duplication (ITD), is correlated 
with poor prognosis [15].
The tissue-specific pattern of Fyn mRNA indicates 
that it is more expressed in normal NK and T cells respect 
to other human tissues [16].
Tintori et al., by a structure-based drug design 
protocol and following hit-to-lead optimization, found 4c 
pyrazolo[3,4-d]pyrimidine compound driving inhibition 
of Fyn phosphorylation with a nanomolar range in an 
enzymatic cell-free assay. Moreover, the compound 
showed anti-proliferative activities against different cancer 
cell lines [17].
Therefore, in the present study we investigated the 
expression of Fyn in NK leukemic cells and the effect of 
4c pyrazolo[3,4-d]pyrimidine compound in NK cell lines 
and in primary cells from chronic leukemic neoplasms.
RESULTS
Fyn is highly expressed in NK leukemic cells
In order to quantify the presence of Fyn in NK 
leukemic cells, we firstly assessed its mRNA expression 
levels in peripheral blood mononuclear cells (PBMCs) 
from 10 healthy donors (HDs) and 8 CLPD patients by 
quantitative Real Time-Polymerase Chain Reaction 
(qRT-PCR). Fyn level was significantly up-regulated in 
PBMCs from CLPD patients compared to HDs (p < 0.001; 
Figure 1A). We also analyzed Fyn protein level by western 
blotting (WB) in PBMCs of 3 HDs, 3 CLPD patients and 
in two NK cell lines, KHYG1 and NK92. We observed a 
high level of Fyn protein in PBMCs from chronic patients 
and in NK leukemic cell lines respect to PBMCs from 
HDs (Figure 1B).
4c pyrazolo[3,4-d]pyrimidine compound reduced 
cell viability, induced apoptosis and cell cycle 
arrest in NK leukemic cells
We treated two cell lines (KHYG1 and NK92), 3 
PBMCs from HDs and NK cells isolated from 3 HDs 
with 4c pyrazolo[3,4-d]pyrimidine compound or with 
dimethyl sulfoxide (DMSO) vehicle control at different 
concentrations (2–10 µM) for 24, 48 and 72 hours, 
cultured with IL2. After 4c treatment, we performed 
viability test which showed that 4c compound reduced 
viability of both cell lines in a dose-dependent manner. 
The effect was observed at 24 hours and remained constant 
in the other time points (Figure 2A). Importantly, both 
cell lines needed a significantly lower drug concentration 
(p < 0.01) to reach 50% reduction of viability (EC50) 
(Table 1). Interestingly, 4c compound had negligible effect 
in PBMCs and in purified NK cells from HDs (Figure 2A). 
Same results were obtained in primary NK cells from 
HDs treated with 4c compound and cultured without IL2 
(Supplementary Figure S1).
To further investigate cell death mechanism induced 
after treatment, we performed apoptosis and cell cycle 
analysis on KHYG1 cell line by cytometric analysis of 
Annexin V/propidium iodide (PI) and PI, respectively. 
After treatment with 4c compound at 4 µM for 24 hours, 
we observed a significant increase of apoptotic cells 
(p < 0.001) and cell cycle arrest in G2/M phase in treated 
KHYG1 respect to their control (Figure 2B–2C).
Fyn phosphorylation is reduced after 4c 
compound treatment and it decreased Akt and 
P70 S6 kinase activation
To verify Fyn inhibition we performed its 
immunoprecipitation in KHYG1 cell line treated with 
4c compound or with DMSO vehicle control and we 
detected its phosphorylation. We observed that Fyn 
phosphorylation significantly decreased after treatment 
(p < 0.01; Figure 3A).
We also explored, by WB, the activation of two 
protein involved in Fyn pathway, Akt and P70 S6 
kinase. Our data showed that there was a decrease of 
phosphorylation of Akt and P70 S6 kinase after treatment 
with 4c compound (p < 0.05; Figure 3B).
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Gene expression and protein profile of treated 
NK leukemic cells showed the activation of 
apoptotic pathways
We performed gene expression profile (GEP) 
analysis of KHYG1 cell line after 4 µM drug incubation 
at 24 hours compared to control. A total of 697 genes 
(297 up-regulated vs 400 down-regulated genes) were 
differentially expressed. Ingenuity Pathway Analysis (IPA) 
gene ontology analysis demonstrated that most of genes 
were involved in cellular growth, death, development and 
cell cycle (Table 2). Moreover, analysis carried out with 
DAVID let us to cluster all genes in the same functions 
indicated by IPA. In fact, the first up-regulated cluster 
genes [e.g. BCL2-like 13, Caspase-Related Inducer 
of Apoptosis (CFLAR), DNA Fragmentation Factor 
Alpha (DFFA) and Fas Ligand] included pro-apoptotic 
functions (Figure 4A and Supplementary Material, 
Table S1); conversely, the first down-regulated cluster 
genes [e.g. Survivin, Cell Division Cycle 34, Aurora 
Kinase A] included pro-survival functions such as cell 
cycle progression, cell division, mitosis (Figure 4B and 
Supplementary Material, Table S2).
We validated GEP data by qRT-PCR confirming 
the down-regulation of anti-apoptotic gene, Survivin 
(p < 0.05), and the up-regulation of two pro-apoptotic 
genes, CFLAR (p < 0.05) and DFFA (p < 0.001), in 
KHYG1 treated vs control (Figure 4C).
Subsequently, to corroborate apoptosis and GEP 
data, we also performed an array analysis of multiple 
apoptotic proteins after treatment. As expected, we 
observed a low expression of anti-apoptotic proteins as 
cellular Inhibitors of Apoptosis Protein 1 (cIAP1), Claspin, 
Clusterin, Heat Shock Protein32 (HSP32), Livin, and high 
expression of apoptotic ones as cleaved caspase 3, TRAIL 
receptor 2 (TRAIL-R2) and Fas (Figure 4D).
In order to validate protein array, we showed a 
significantly increase of cleaved caspase 3 level (p < 0.05) 
in 4c compound treated cell line by WB (Figure 4E).
4c pyrazolo[3,4-d]pyrimidine compound induced 
cytotoxic effect and cell cycle arrest in primary 
NK leukemic cells
In order to evaluate Fyn inhibitor effects on primary 
cells, we exposed PBMCs from CLPD patients to 4 µM of 
4c compound for 24 hours and we evaluated cell viability 
by trypan blue count. We observed a decrease of 30% of 
viable cells in treated PBMCs respect control (Figure 5A). 
Notably, in treated NK cells from leukemic patients there 
was an increase of active caspase 3/7 level indicating an 
apoptosis caspase 3-mediated (p < 0.01, Figure 5B).
Table 1: EC50 obtained in two cell lines and PBMCs and in purified NK cells from HD samples 
after 4c compound treatment (P value is < 0.01 for both cell lines vs HDs) (n.c.: not calculable)
EC50 (µM)
KHYG1 5.4
NK92 10.6
HDs 59
HD-NK cells n.c.
Figure 1: Fyn is over-expressed in NK malignant cells. (A) qRT-PCR of Fyn mRNA in PBMCs from 10 HDs and from 8 patients 
with CLPD (UPN: 1–8). Statistical significance was determined using an unpaired t test and P-value is indicated by asterisk: ***p < 0.001. 
(B) WB analysis of Fyn in 3 HDs, 3 CLPD patients (UPN: 6–7) and two NK cell lines, KHYG1 and NK92. Quantification of Fyn protein 
levels was normalized with β-actin bands.
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To better elucidate 4c effects on primary NK cells, 
we sorted CD56+ NK cells from 3 PBMCs of CLPD 
patients and we exposed them to 4c compound for 24 
hours. After incubation time, we evaluated viability by 
trypan blue count, proliferation by PKH67 labeling, 
apoptosis and cell cycle by Annexin V/7-Amino-
Actinomycin D (7ADD) and PI respectively. Firstly, we 
observed a decrease of 37% of viable cells (Figure 6A). 
Furthermore, we analyzed proliferation, apoptosis and 
caspase 3/7 rate both on CD56+/CD16+ and CD56+/
CD16− after 4c treatment. We noted a reduction of 
proliferation in both CD56+/CD16+ and CD56+/CD16−
cells (Figure 6B). Moreover, in both treated populations, 
we observed a significantly increased apoptosis 
compared to their respective control (+ 17% in CD56+/
CD16+ cells and + 5.4% in CD56+/CD16− cells; p < 0.01 
and p < 0.05 respectively) (Figure 6C). The 4c effect on 
apoptosis was also confirmed by increased expression 
Figure 2: 4c compound reduced cell viability inducing apoptosis and cell cycle arrest in NK leukemic cells. (A) Viability 
of KHYG1, NK92, 3 PBMCs from HDs (HDs) and NK primary cells sorted from 3 HDs (HD-NK cells) was evaluated by MTS assay 
after treatment with 4c compound at different concentration (2–10 µM) for 24–72 hours. Results are expressed as percent of cell viability 
normalized to DMSO-treated control cells. The bar-graphs represent mean with S.D. from three independent experiments. (B) Apoptosis 
and (C) cell cycle analysis were evaluated by flow cytometer in NK cell line after 4c or DMSO vehicle treatment at 4 µM for 24 hours. Dot 
plots and cell cycle histograms show a single representative experiment, the bar-graphs represent mean with S.D. from three independent 
experiments. P-value is indicated by asterisk: ***p < 0.001.
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of caspase3/7 levels in both population (+ 2.5% in 
CD56+/CD16+ cells and + 8% in CD56+/CD16− cells; 
p < 0.01 and p < 0.05 respectively) (Figure 6D). Cell 
cycle analysis after 4c treatment showed that there was 
an increase of number of NK primary cells in G0/G1 
phase (Figure 6E).
4c compound treatment induced phenotype 
changes in NK primary cells
To evaluate if 4c compound influence NK cell 
activation, we sorted CD56+ NK cells from 3 PBMCs 
of CLPD patients and we exposed them to 4c compound 
for 24 hours to study cell phenotype changes. We 
analyzed the expression of two markers related to NK 
activation, CD38 and CD25. We observed that there was 
a decrease of CD38 expression and similar expression 
of CD25 after treatment respect to control in NK cells 
(Figure 7A–7B).
DISCUSSION
NK cell-type large granular lymphocyte leukemia is 
a rare neoplasm divided in two subtype which could be 
considered different and independent neoplasms because 
they have distinct clinical course and management. 
Chronic lymphoproliferative subtype is characterized 
by indolent clinical course lacking effective therapeutic 
approaches [18]; the number of circulating NK cells 
remains stable for long periods of time and some cases 
have been reported to show spontaneous regression. On 
the other hand, aggressive NK leukemia subtype is a 
fulminant disorder which is not curable.
By tissue-specific pattern of mRNA [16], it was 
identified Fyn like as a gene more expressed in normal 
NK cells respect to other tissues. It is required to control 
cytotoxicity and cytokine production in NK cells [19, 20], 
and it has a critical role in NK and T-cell development and 
activation [9, 21].
Figure 3: Inhibition on Fyn phosphorylation by 4c compound decreased Akt and P70 phosphorylation. WB analysis of 
(A) phospho-Fyn and (B) total and phosphorylated Akt and P70 S6 kinase in NK cell line treated with 4c compound compared to control. 
Protein levels were normalized on β-actin signals. Bar-graphs represent mean with S.D. from three independent experiments. P-values are 
indicated by asterisk: *p < 0.05, **p < 0.01.
Table 2: Molecular and cellular functions of up- and down-regulated genes resulting from IPA 
gene ontology analysis in GEP analysis of 4c compound vs DMSO treated KHYG1 cells
Molecular and Cellular Functions p-value range Molecules
Cellular Growth and Proliferation 7.29E-04/5.16E-15 259
Cellular Function and Maintenance 6.79E-04/5.82E-14 126
Cell Death and Survival 7.81E-04/6.66E-14 239
Cellular Development 5.67E-04/6.26E-13 227
Cell Cycle 7.64E-04/2.48E-11 126
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Figure 4: Activation of apoptotic pathways in 4c treated cell line. (A–B) Bar-graphs of the first cluster up-regulated (A) and 
down-regulated (B) genes resulting by DAVID bioinformatic tool in GEP analysis of KHYG1 treated with 4c compound or with DMSO 
control. (C) qRT-PCR of Survivin, CFLAR and DFFA in KHYG1 treated vs control. Bar-graphs represent mean with S.D. from three 
independent experiments. (D) Bar-graphs of protein levels resulted from apoptotic protein array and (E) WB analysis of caspase 3 in 
KHYG1 treated vs control. P-values are indicated by asterisk: *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 5: 4c treatment reduced viability and induced caspase 3-mediated apoptosis in PBMC from CLPD patients. (A) 
Trypan blue count was performed in primary cells, isolated from 3 HDs and 3 CLPD patients (UNP: 6–8) and (B) Caspase 3/7 activity assay 
on 3 CLPD patients (UNP: 6–8) after 24 hours of treatment with 4c compound at 4 µM concentration. P-values are indicated by asterisk: 
*p < 0.05, **p < 0.01.
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Since NK leukemia is characterized by an outgrowth 
of CD3− CD16/56+ cells, Fyn could be a possible target 
in this hematological disease. In fact, analyzing its 
expression in NK leukemic cells, we found an increased 
Fyn transcript level in PBMCs from CLPD patients 
respect to HDs. Interestingly, Fyn protein levels was 
higher in CLPD patients and in NK cell lines respect 
to HDs. In these last samples Fyn protein level was not 
detectable, perhaps for the lower percent of NK cells in 
HD-PBMCs (< 10%) respect to CLPD patients (20–40%), 
to equal protein loaded lysate in western blotting assay. 
The over-expression of Fyn is documented in different 
cancers, such as CML, brain, prostate and breast tumors 
where it facilitates the growth, the migration of tumor cells 
and genomic instability [22–26]. Recently, FYN mutations 
were found in peripheral T-cell lymphomas where they 
impaired DNA damage response and escape from immune 
surveillance [14].
Our previous data showed that 4c pyrazolo[3,4-d]
pyrimidine compound is able to inhibit Fyn kinase in a 
cell-free assay and to induce apoptosis and cell cycle arrest 
in CML cell line [17].
In this paper, for the first time, we investigated the 
effect of this compound on NK cell leukemia.
Figure 6: 4c compound treatment reduced cell viability and proliferation, induced caspase 3-mediated apoptosis and 
cell cycle arrest in primary NK leukemic cells. On 4c treated or not primary NK cells sorted from PBMCs of 3 NK-CLPD patients 
(UPN: 6–8) (A) Trypan blue count, (B) PKH67 proliferation test, (C) Apoptosis and (D) Caspase 3/7 activity assay, (E) Cell cycle analysis 
were performed. Proliferation, apoptosis and caspase 3/7 level were analyzed on CD56+/CD16+ and CD56+/CD16− NK cell populations. 
P-values are indicated by asterisk: *p < 0.05, **p < 0.01. (MFI= mean fluorescent intensity).
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First of all, we demonstrated that 4c reduced cell 
viability in NK cell lines. Interestingly, it had no effect on 
both PBMCs and NK purified cells from HDs.
Since it was discovered previously that exposure 
to stimulatory factors such as the cytokine IL2 enhanced 
NK cell potency significantly [27], we cultured primary 
HD-NK cells with and without IL2 in order to evaluate 
if 4c compound could have diverse effect on NK cells 
differently activated. We observed that 4c compound 
had no effect on HD-NK cell viability in both culture 
conditions. So the presence of IL2 not influenced response 
to 4c treatment.
These results allowed us to conclude that 4c 
compound acted only on NK leukemic cells and not on 
healthy NK cells. Moreover, it not influenced viability of 
other PBMC population.
We obtained different percent of viability reduction 
in cell lines after 4c treatment. More precisely, the major 
effect was observed in KHYG1 respect to NK92. The 
diverse response to 4c compound of the two cell lines 
could be due to their different origin. In particular, KHYG1 
was established from peripheral blood of a woman with 
aggressive NK leukemia at diagnosis, while NK92 was 
established from a man with non-Hodgkin’s lymphoma 
with large granular lymphocytes, more corresponding to 
chronic subtype.
We decided to study in deep the viability reduction 
in NK aggressive KHYG1 cells and demonstrated that 4c 
induced a G2/M cell cycle arrest and a significant apoptosis.
Recent studies show the possibility to conduct NK 
malignant cells to apoptosis thus supporting a possible 
therapeutic option. Quoc Trung L et al. showed that 
resveratrol induced G0/G1 cell cycle arrest and apoptosis 
in NK leukemic cell lines by inhibiting STAT3 signaling 
[28]; similar results were obtained by Sun X et al. using a 
combination of drugs, vorinostat and cladribine [29].
To demonstrate that effects on cell viability 
were due to Fyn inhibition, we confirmed its reduced 
phosphorylation. These findings are in agreement with 
Ninio-Many L et al. who revealed that miR-125a-
3p causes an arrest of cell cycle at G2/M stage and a 
decreases cell viability in a Fyn-dependent manner [30]. 
Other studies, in glioma and prostate cells, revealed 
similar results after Fyn down modulation [23, 31]. All 
this confirms the fact that Fyn is considered an important 
regulator of cell cycle, growth and proliferation [32–34].
To the best our knowledge, this is the first study 
concerning the Fyn targeting in NK malignancies.
Moreover, we investigated Fyn downstream 
pathway. Since some studies have shown that Src kinases, 
including Fyn, may be required for Akt activation by 
a tyrosine phosphorylation-dependent mechanism 
[35, 36], we also investigated the Akt behavior after 4c 
treatment and we observed that Fyn inhibition reduces 
Akt phosphorylation. Additionally, our data showed a 
reduction of P70 S6 kinase phosphorylation, an important 
downstream target of Akt involved in cell survival and in 
apoptosis inhibition [37, 38].
Figure 7: 4c compound treatment induced phenotype changes in NK primary cells. On 4c primary NK cells sorted from 
PBMCs of 3 CLPD patients (UPN: 6–8) (A) CD38 and (B) CD25 expression were evaluated after 4c treatment. P-values is indicated by 
asterisk: ***p < 0.001. (MFI = mean fluorescent intensity)
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Furthermore, GEP analysis of 4c treated KHYG1 
cells confirmed the down-regulation of pro-survival gene 
pathways and the up-regulation of apoptotic functions. 
In particular, we validated by qRT-PCR the reduction of 
Survivin, and the increase of CFLAR and DFFA mRNA. 
Survivin, a member of the inhibitor of apoptosis protein 
(IAP) family, regulates leukemic NK cell survival via 
ERK/MAPK signaling [39]. Interestingly, Liu et al. 
demonstrated that targeting of survivin may be a possible 
therapeutic approach for NK leukemia because it is highly 
expressed in both aggressive and chronic leukemic NK 
cells respect to normal ones [40].
The first up-regulated gene, CFLAR, also known as 
Casper/cFLIP, is a FADD- and Caspase-Related inducer 
of apoptosis and its over-expression induces apoptotic 
cell death [41–43]. It also play a critical role in autophagy, 
necroptosis and apoptosis in T-lymphocytes [44] and it 
has prognostic and therapeutic relevance in acute myeloid 
leukemia (AML) [45] as well as in development of drug 
resistance [46]. DFFA gene is the substrate for caspase 3 
and triggers DNA fragmentation during apoptosis [47, 48].
In addition, the protein array confirmed the down 
modulation of survivin, of other members of IAP family, 
such as cIAP-1, XIAP, livin [49, 50] and of cell cycle 
regulators such as Cluspin [51], and the high modulation 
of pro-apoptotic ones, such as cleaved caspase 3.
Interestingly, dot blot assay showed a decrease of 
Cytochrome C and Smac/DIABLO and an increase of 
Fas levels suggesting the activation of extrinsic apoptotic 
pathway [52]. We also confirmed, by western blotting 
(WB), the presence of cleaved caspase 3 after treatment 
letting us to assert that 4c Fyn inhibitor compound is 
able to induce apoptotic death caspase 3-mediated in NK 
malignant cells.
Finally, we demonstrated that 4c pyrazolo[3,4-d]
pyrimidine compound reduced viability and induced 
apoptosis in PBMCs and in NK cells from patients with 
NK leukemia.
In human PBMCs the NK cells can be divided 
on the basis of the expression of CD56 and CD16 
markers. CD56+/CD16+ and CD56+/CD16− populations 
show different proliferation, redox state and function. 
Specifically, CD56+/CD16− cells are responsible for 
immunoregulatory cytokines production, CD56+/CD16+ 
cells are responsible for the cytotoxic lysis of target 
cells [53–54]. On the basis of these considerations, we 
analyzed the 4c effects on both NK purified population. 
We demonstrated that there was a reduction of viability 
after treatment but also a reduction of proliferation and 
an increase of apoptosis caspase dependent in both 
population CD56+/CD16+ and CD56+/CD16−. From cell 
cycle analysis, 4c compound resulted to be cytostatic, in 
fact there was an increase of G0/G1 phase.
In order to study the 4c effect on NK cell phenotype, 
we evaluated two important surface molecule involved in 
NK cells activation, such as CD38 and CD25 [55]. We 
demonstrated that 4c treatment reduced the expression 
of CD38, while CD25 expression remained constant. It 
means that NK treated cells could be slightly active.In 
summary, the present study demonstrated that Fyn kinase 
has a role in the pathogenesis of NK leukemia. Moreover, 
inhibition of Fyn phosphorylation by 4c pyrazolo[3,4-d]
pyrimidine compound induces apoptosis and cell cycle 
arrest in NK leukemic cells.
Fyn targeting by 4c compound could represent a 
potential and possible strategy for NK leukemia treatment.
MATERIALS AND METHODS
Patients, cell lines and chemical
Peripheral blood samples from HDs and NK-
CLPD (patient characteristics are shown in Table 3) were 
obtained with informed consent. PBMCs were isolated 
by Ficoll-hypaque gradient separation and NK cells were 
isolated by cell sorter MoFlo Atrios (Beckman Coulter, 
Brea, California, USA) by labeling with anti-CD56 
phycoerythrin (PE) (Becton Dickinson, BD, Franklin, NJ, 
USA). Human NK cell lines, KHYG1 and NK92 [56, 57], 
were purchased from Leibniz-Institut DSMZ – Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH 
and American Type Culture Collection, respectively. 
NK primary cells and cell lines were cultured in RPMI 
1640 (Gibco, Life technologies, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (FBS, Gibco), 
1% of penicillin-streptomycin (Gibco) and 10 ng/ml 
interleukin-2 (IL-2, Miltenyi Biotec, Auburn, CA) at 37°C 
and 5% CO2.
4c pyrazolo[3,4-d]pyrimidine compound, given by 
Lead Discovery Siena s.r.l. (patent: WO2016066755), was 
dissolved in DMSO (Sigma Aldrich, St Louis, MO, USA) 
and diluted in FBS for cell treatments.
RNA extraction and qRT-PCR
Total RNA was extracted with AllPrep DNA/RNA/
miRNA Universal Kit (Qiagen GmbH, Hilden, Germany) 
according to the manufacturer’s instructions. Reverse 
transcription was performed using Transcriptor First Strand 
cDNA Synthesis kit (Roche, Indianapolis, IN, USA).
mRNA expression was evaluated by qRT-
PCR, performed on Light Cycler 480 II (Roche) with 
intercalating dye SYBR Green I Master Mix (Roche) 
using 100 ng cDNA at the following conditions: 95°C for 
10 min, 45 cycles at 95°C for 10 sec, 60°C for 10 sec, 
72°C for 15 sec. Each sample was analyzed in triplicate. 
Relative mRNA expression values were normalized 
using GAPDH as reference gene and Universal Human 
Reference RNA (Qiagen) as calibrator and calculated on 
the basis of the E-∆∆Cp method.
The primer sequences of human Fyn, GAPDH, 
Survivin, CFLAR and DFFA were as follows: Fyn forward 
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5′-AGATTGCTGACTTCGGATTG-3′, Fyn reverse 
5′-CAGACTTGATTGTGAACCTC-3′, GAPDH forward 
5′-AGGCTGAGAACGGGAAGC-3′, GAPDH reverse 
5′-CCATGGTGGTGAAGACGC-3′, Survivin forward 
5′-AGAACTGGCCCTTCTTGGAGG-3’, Survivin 
reverse 5′-CTTTTTATGTTCCTCTATGGGGTC-3′, 
CFLAR forward 5′-TGGTAAGGCATGCTTCCAGA-3′, 
CFLAR reverse 5′-ACAGTATCAGAAGGTGGGGC-3′, 
DFFA forward 5′-CACTCCAACAGGTGCTTGAC-3′, 
DFFA reverse 5′-AGTGCAGTAAGGATGTGGCT-3′.
Gene expression profile analysis
Total RNA was quantified with a NanoDrop 2000c 
spectrophotometer (Thermo Scientific, Wilmington, 
DE, USA) and its quality was assessed by capillary 
electrophoresis on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Inc, Santa Clara, CA) using RNA 6000 
Nano Assay Kit (Agilent). Only samples with RNA 
integrity number (RIN) > 7 were used.
Samples preparation, hybridization, staining and 
scanning of Illumina HumanHT12 v4.0 Expression 
BeadChip array (Illumina Inc., San Diego, CA, USA) 
on HiScanSQ system (Illumina Inc.) was performed as 
described before [58].
The intensity files were loaded into the Illumina 
Genome Studio software for quality control and gene 
expression analysis. Quantile normalization algorithm 
was applied on the data set to correct systematic errors, 
values below a detection score of 0.05 were filtered out 
and missing values were imputed. Differently expressed 
genes (DEGs) were selected with differential score 
(DiffScore) cutoff set at ± 13 (p < 0.05). Microarray 
data were submitted to Array Express under accession 
number E-MTAB-4536. DEGs list was used to evaluate 
the functional behavior in terms of Biological Processes 
performing an enrichment analysis with IPA (Ingenuity 
Systems; Mountain View, CA, USA). DEGs list was 
uploaded also into DAVID bioinformatic tool [59] and 
functional annotation clustering was evaluated separately 
for up- and down-regulated genes.
Western blotting analysis
Cells were lysed as previously reported [60]. 80 µg 
was subjected to sodium dodecyl sulfate polyacylamide 
gel electrophoresis on a 10% gel under reducing conditions 
and then electrotransferred onto a polyvinylidene 
difluoride membranes using Trans Blot Turbo Transfer 
System (BioRad, Hercules, CA, USA). Membranes were 
probed with primary antibodies directed against Fyn, 
phospho-Src Family (Tyr416), phospsho-AKT (Ser473), 
Akt, phospho-P70 S6 kinase (Thr389), P70 S6 kinase, β 
actin (Cell Signaling, Beverly, MA, USA), active caspase 
3 (Abcam, Cambridge, UK) and then incubated with 
secondary antibody (horseradish peroxidise-conjugated 
goat anti-mouse or anti-rabbit; Cell Signaling). Immune 
complexes were detected by ECL chemiluminescence 
system (Bio-Rad Laboratories), as recommended by the 
manufacturer. Densiometric analysis was performed using 
BioRad Image Lab 4.1 software. The intensity of bands of 
all proteins was normalized to the β actin signal.
Immunoprecipitation
Protein immunoprecipitation was carried out starting 
from 1 mg of total protein extracts. Lysates were pre-
cleared by incubating with protein A/G-Agarose (Santa 
Cruz Biotechnology) for 1 hour, subsequently incubated 
with anti-Fyn antibody for 18 hours and then with fresh 
A/G-Agarose for 2 hours. All incubation were conducted 
at 4°C. The product was collected by centrifugation and 
washed twice. WB analysis was performed as previously 
reported.
Proteome profiler array
Protein extract of KHYG1 cell line, treated with 
4c compound at 4 µM or with DMSO vehicle control 
for 24 hours, were subjected to the human apoptosis 
array following the manufacturer’s instructions (Human 
Apoptosis Array kit, R&D Systems, Abingdon, UK).
Table 3: Clinical characteristics of NK-CLPD patients
UPN Gender Age NK cells
1 F 65 > 60%
2 M 63 > 60%
3 M 49 40–60%
4 M 49 40–60%
5 M 45 40–60%
6 F 77 30–40%
7 M 45 30–40%
8 M 51 20–30%
Abbreviations: UPN, unique patient number; F, female; M, male.
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Cell viability
KHYG1 and NK92 cell lines, PBMCs and 
NK cells from HDs were seeded into 96-well plates 
(3 × 104 cells/100 µl) and incubated with 4c compound 
at increasing concentrations (2–10 µM) for 24, 48 and 
72 hours. Cells treated with DMSO vehicle were used as 
control. Cell viability was determined using the CellTiter 
96 Aqueous One Solution assay kit (MTS, Promega, 
Madison, WI, USA). The optical density was measured 
at 492 nm. Cellular viability was calculated as percentage 
of viable cells compared with control. All experiments 
were conducted in triplicate. EC50 values were obtain 
by GraphPad Prism (GraphPad Prism, San Diego, CA). 
Viability of cell lines and primary NK cells from NK-
CLPD was assessed by Trypan blue dye count method.
Functional tests
KHYG1 and NK cells from NK-CLPD samples 
were treated with 4 µM of 4c compound or with DMSO 
vehicle control for 24 hours (cell density 3 × 105 cells/ml) 
and used in:
Apoptosis assay
Apoptosis of KHYG1 was evaluated by cytometric 
analysis of Annexin V and Propidium Iodide (PI)-stained 
cells using fluorescein isothiocyanate (FITC) Annexin V 
Apoptosis Detection kit I (BD). NK cells isolated from 
NK-CLPD samples were firstly labeled with anti CD56 
PE and CD16 allophycocyanin (APC), than labeled with 
Annexin V and 7-Amino-Actinomycin D (7ADD, BD) 
to evaluate apoptosis. Stained cells were acquired using 
FACSCalibur flow cytometer and analyzed by CellQuest 
Pro software (BD). Single positive for Annexin V and 
double positive for Annexin V and PI/7ADD cells were 
interpreted as signs of early and late phases of apoptosis 
respectively.
Cell cycle analysis
After treatment KHYG1 cells were fixed in cold 
ethanol 70% for 1 hour, then labeled with PI/RNase 
staining solution for 30 minutes. Instead, after treatment, 
NK cells from NK-CLPD samples were labeled with anti-
CD56 PE and anti-CD16 APC, fixed and permeabilzed by 
Intracell kit (Immunostep, S.L. Avda), then labeled with 
7ADD/RNase staining solution for 30 minutes. Samples 
were acquired by FACSCalibur (BD). Data were analyzed 
by ModFit LT Software (Verity Software House).
Caspase 3/7 activity assay
NK primary cells, treated with 4c compound or 
with DMSO vehicle for 24 hours (cell density 1 × 106/ml), 
were labeled with anti-CD56 PE and anti-CD16 APC, 
then incubated with 1 µM of CellEvent caspase3/7 Green 
Detection Reagent (Life technologies, Carlsbad, CA, 
USA) in complete medium at 37°C for 30 minutes as 
manufacturer’s protocol. Stained cells were analyzed by 
FACSCalibur cytometer (BD).
Proliferation assay
NK primary cells were stained with PKH67 (PKH67 
Green Fluorescent Cell Linker Kit for General Cell 
Membrane Labeling, Sigma Aldrich) as manufacturer’s 
protocol, treated with 4c compound or with DMSO 
vehicle control for 24 hours and analyzed by FACSCalibur 
cytometer (BD).
Analysis of NK phenotype
NK primary cells, treated with 4c compound or with 
DMSO vehicle control for 24 hours, were labeled with 
anti-CD25 FITC, anti CD38-APC (BD) and analyzed by 
FACSCalibur cytometer (BD).
Statistical analysis
Statistical significance was determined using a 
paired or unpaired t test by GraphPad Prism. All error bars 
represent the standard deviation (SD) of the mean.
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